Article
Oncology
Xue Yang, Lili Wang, Xiangfeng Jin, Rongjian Xu, Zhuang Yu, Hongmei Li, Haijun Lu, Ning An
Summary: This study found that ER positivity was significantly associated with poor prognosis in male LUSC patients with pIIIA-N2 disease. ER expression predicted a worse disease-free survival, overall survival, local recurrence-free survival, and distant metastasis-free survival. Therefore, PORT may be more beneficial for ER negative LUSCs in male, and the examination of ER status could help identify patients suitable for PORT.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Sacha Rothschild, Alfred Zippelius, Eric Eboulet, Spasenija Savic Prince, Daniel Betticher, Adrienne Bettini, Martin Frueh, Markus Joerger, Didier Lardinois, Hans Gelpke, Laetitia A. Mauti, Christian Britschgi, Walter Weder, Solange Peters, Michael Mark, Richard Cathomas, Adrian F. Ochsenbein, Wolf-Dieter Janthur, Christine Waibel, Nicolas Mach, Patrizia Froesch, Martin Buess, Pierre Bohanes, Gilles Godar, Corinne Rusterholz, Michel Gonzalez, Miklos Pless
Summary: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, perioperative treatment with durvalumab in addition to neoadjuvant chemotherapy is safe and improves treatment outcomes, achieving a high major pathologic response rate and an encouraging 1-year event-free survival rate of 73% beyond historical chemotherapy data.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia
Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Article
Oncology
Minxia Zhu, Shaomin Li, Liyue Yuan, Shiyuan Liu, Jianzhong Li, Danjie Zhang, Jia Chen, Jiantao Jiang, Zhengshui Xu
Summary: This study aims to evaluate the effect of postoperative radiotherapy (PORT) on survival in patients with IIIA-N2 non-small cell lung cancer (NSCLC) who underwent surgery. The results of Cox proportional hazards regression analysis and propensity score matching analysis showed that PORT was not associated with improved survival in patients with IIIA-N2 NSCLC. Therefore, PORT does not provide a survival benefit for these patients.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Suyu Wang, Zhiyuan Zhang, Yang Gu, Xin Lv, Xuan Shi, Meiyun Liu
Summary: The study found that for patients with stage IIIA/N2 non-small cell lung cancer, both sublobectomy and lobectomy can improve survival rates, with lobectomy showing better outcomes than sublobectomy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sunyi Zheng, Jiapan Guo, Johannes A. Langendijk, Stefan Both, Raymond N. J. Veldhuis, Matthijs Oudkerk, Peter M. A. van Ooijen, Robin Wijsman, Nanna M. Sijtsema
Summary: This study aimed to develop and evaluate a prediction model for 2-year overall survival (OS) in stage I-IIIA non-small cell lung cancer (NSCLC) patients who received definitive radiotherapy. The hybrid model, which integrated clinical variables and image features from pre-treatment CT scans, achieved reasonable performance and has the potential to identify high mortality risk patients and guide clinical decision making.
RADIOTHERAPY AND ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Necati Citak, Laura Guglielmetti, Yunus Aksoy, Ozgur Isgorucu, Muzaffer Metin, Adnan Sayar, Isabelle Opitz, Didier Schneiter, Walter Weder, Ilhan Inci
Summary: The study compared survival rates between completely resected stage IIIA/B lung cancer patients, finding significant differences in survival between the T3 N1-T4 N0/1 subset and the T1/2 N2 subset. This finding was validated with another center's database, identifying age, stage IIIB, and pN2 as independent negative prognostic factors.
ANNALS OF THORACIC SURGERY
(2021)
Article
Cardiac & Cardiovascular Systems
Jarrod Predina, Raiya Suliman, Alexandra L. Potter, Nikhil Panda, Kevin Diao, Michael Lanuti, Ashok Muniappan, Chi -Fu Jeffrey Yang, Jeffrey Yang
Summary: This study aimed to evaluate the impact of postoperative radiotherapy using intensity-modulated radiotherapy (IMRT) on the survival of patients with stage IIIA-N2 non-small cell lung cancer (NSCLC). The analysis found no significant difference in overall survival between patients who received postoperative IMRT and those who did not.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2023)
Review
Oncology
Ying Yang, Cheng Shen, Jingjing Shao, Yilang Wang, Gaoren Wang, Aiguo Shen
Summary: The study found that patients with unresectable stage IIIA-N2 LCNEC and LUSC have worse LCSS than LUAD. The first prognostic nomogram constructed accurately predicts the survival of patients with different histological types, providing a practical tool for clinicians to assess prognosis and stratify prognostic risks.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Fangqiu Fu, Wenrui Sun, Jinsong Bai, Chaoqiang Deng, Difang Zheng, Yuan Li, Yang Zhang, Haiquan Chen
Summary: This study reports the long-term outcomes for patients with stage IIIA-N2 NSCLC and finds that R0 resection, single-station N2 disease, and adjuvant therapy are associated with improved survival rates.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Chenghao Qu, Rongyang Li, Jingyi Han, Weiming Yue, Hui Tian
Summary: The study found that the long-term outcome was the worst in N2 NSCLC patients who received chemotherapy and postoperative radiotherapy. Subgroup analysis showed that the influence of age on survival outcome was limited to patients who received chemotherapy and neoadjuvant radiotherapy. Patients over 65 years of age who received chemotherapy and neoadjuvant radiotherapy had significantly worse prognoses than those in the chemotherapy group.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Oncology
Xiao-Hong Xie, Ze-Jiang Zhan, Yin-Yin Qin, Ju-Hong Jiang, Wei-Qiang Yin, Rong-Hui Zheng, Shi-Yue Li, Cheng-Zhi Zhou
Summary: This case report demonstrates successful neoadjuvant treatment with ALK inhibitor in a locally advanced NSCLC patient, with significant reduction of lesions observed and prolonged overall survival of 68 months post-surgery. The use of ALK inhibitors in both neoadjuvant and adjuvant settings may be a promising approach for ALK-positive locally advanced NSCLC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Larisa Shagabayeva, Beverly Fu, Nikhil Panda, Alexandra L. Potter, Hugh G. Auchincloss, Arian Mansur, Chi-Fu Jeffrey Yang, Lana Schumacher
Summary: This study compares the outcomes of open, robotic, and VATS lobectomy for stage II-IIIA NSCLC. The results show that MIS lobectomy has a shorter length of stay compared to open lobectomy, with no significant differences in mortality, readmission, and survival. Similarly, robotic lobectomy has a shorter length of stay and lower conversion rate compared to VATS lobectomy, with no significant differences in mortality, readmission, and survival.
ANNALS OF THORACIC SURGERY
(2023)
Article
Oncology
Maria Laura Gritti Paes de Barros, Vinicius G. Silva, Frederico Rafael Moreira, Stela V. Perez, Riad N. Younes, Fernando Conrado Abrao
Summary: This study evaluated the prognostic factors, 5-year overall survival (OS), and cancer-specific survival (CSS) of patients with resectable stage III NSCLC. The results showed improvement in OS and CSS over the past 19 years for patients with resectable stage III NSCLC. Squamous cell carcinoma was associated with lower OS and CSS compared to adenocarcinoma.
JOURNAL OF SURGICAL ONCOLOGY
(2023)